Skip to content

Author

Lara Gabrielle Lim

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Actionable Incidental Findings at Baseline Lung Cancer Screening: Identifying Opportunities in a Universal Healthcare System.

PURPOSE To determine the prevalence of actionable incidental findings (AIFs) in a high-risk lung cancer screening cohort within a universal healthcare setting and identify potential opportunities in system-level quality improvement for AIF detection and management. METHODS This retrospective cohort study identified all individuals that presented for a baseline lung cancer screening exam between August 2019 and September 2025. Structured computed tomography (CT) report text was extracted and included an affirmation of whether an AIF was present, a description of the AIF, and a management recommendation. AIF type and prevalence were compared to guideline literature to identify areas of lower-than-expected reporting. Comparisons were performed using t-tests or chi-square tests. RESULTS There were 3169 unique individuals with eligible CT reports (37.2% female, 64.0 ± 5.2 years of age) with 424 AIFs identified in 370 (11.7%) individuals. AIFs were associated with higher body mass index, active smoking, Lung-RADS score, and less common with a personal history of cancer (P < .05). Moderate or severe coronary artery calcification (n = 106, 3.3%), thyroid lesions (n = 43, 1.4%), and interstitial lung abnormalities (n = 41, 1.3%) were most common. Bone mineral density (0%), vertebral fractures (0.1%), and indeterminate adrenal lesions (0.1%) were infrequently reported despite guidelines suggesting clinical relevance. Management recommendations were generally aligned with provincial program-specific guidance. CONCLUSION AIFs were common, but prevalence was relatively low for several key, potentially significant findings. Standardized reporting of AIFs and program-specific guidance is required considering the downstream costs associated with systematic identification of these AIFs.

Adam Gaisinsky, Lara Gabrielle Lim, Hussain Alshimali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.